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MODY is a sub-type of NIDDM. It is characterized by an early age of onset and autosomal 
dominant mode of inheritance. These features, and the availability of large multigenerational 
pedigrees, make MODY useful for genetic studies of diabetes. In the large 5-generational 
RW pedigree, MODY is tightly linked to genetic markers on chromosome 20q. Affected 
subjects in this family show abnormalities of carbohydrate metabolism, varying from 
impaired glucose tolerance (IGT) to severe diabetes. Approximately 30 % of diabetic 
subjects become insulin-requiring, and vascular complications occur. MODY is also linked 
to the glucokinase gene on chromosome 7p and many different mutations associated with 
MODY have been identified in this gene. MODY, due to mutations in the glucokinase 
gene, is a relatively mild form of diabetes with mild fasting hyperglycaemia and IGT in 
the majority. Clinical investigative studies indicate that the genetic or primary defect in 
MODY is characterized by deranged and deficient insulin secretion and not by insulin 
resistance. There are quantitative and qualitative differences in insulin secretory defects 
which differentiate subjects with MODY due to mutation in the gene on chromosome 
20q from those with glucokinase mutations. These differences correlate with the severity 
of diabetes between these two genetic forms of MODY. 
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Introduction 
Maturity onset diabetes of the young (MODY), a relatively 
uncommon subtype of NIDDM, is a valuable model for 
the study of the molecular genetics and pathogenesis of 
NIDDM.u A previous review summarized our expanding 
knowledge of the phenotypic expression, natural history, 
molecular genetics and pathogenesis of MODY.2 This 
presentation gives a condensed version of the previous 
review; it includes additional data on insulin secretion. 
Definition, Phenotypic Expression, and 
Natural History 
MODY is defined as NIDDM characterized by an 
early age of onset and autosomal dominant mode of 
inheritance. 1-4 When MODY is suspected and family 
members are examined biochemically, a diagnosis of 
diabetes can be made almost invariably under the age 
of 25 years, frequently between the ages of 9 and 13 
years, and in some families at an even earlier age. 
Because of autosomal dominant inheritance and early 
age of onset it is possible to collect large multigenerational 
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pedigrees with MODY, a unique feature of this subtype 
of NIDDM. 
The RW pedigree, consisting of more than 360 
presently identified members including 72 known subjects 
with diabetes distributed over 5 generations, has been 
studied and followed prospectively by one of us (SSF) 
since 1958. The propositus, 11-5 (W branch), offspring of 
1-3 had diabetes diagnosed at the age of 41 years (Figure 
1 (a)). He was blind from diabetic retinopathy at the age 
of 61 years and had an amputation for peripheral vascular 
disease. He had five brothers, four of whom had diabetes 
and one who did not. Macrovascular disease including 
myocardial infarctions and peripheral vascular disease 
with gangrene and amputations, as well as microvascular 
disease including retinopathy and blindness are compli-
cations resulting from MODY in the RW pedigree (Figure 
1 ). In addition, there is also evidence of neuropathy. 
In 1958, the 11 non-obese, apparently healthy and 
asymptomatic offspring of 11-5 were recruited for routine 
blood glucose testing. Seven of the 11 were found to 
have abnormal glucose metabolism.3 The older 3 had 
fasting hyperglycaemia (mean 257 mg dl- 1), 3 others 
had diabetic glucose tolerance tests without diagnostic 
fasting hyperglycaemia, and 1 had IGT. 
With follow-up, all have developed fasting hypergly-
caemia. Two have been treated with insulin because of 
eventual unresponsiveness to sulphonylurea drugs, 4 
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Figure 1. Partial pedigree of the RW family. Offspring of 1-1 belong to the R branch. Offspring of 1-3 belong to the W branch. 
Only the offspring of 11-5 (a) and 11-2 (b) of theW branch are shown. All subjects with diabetes were or are non-insulin-dependent 
except IV-144 who is insulin-dependent. Diabetic or IGT offspring of 11-5 of generations 111-V (a) and diabetic offspring 111·3 and 
111-8 (b) and their diabetic offspring are genetic marker (chromosome 20) positive. In addition, nondiabetic IV-143 (a) and IV-21 
(b) are genetic marker (GM) positive (+). In generation V, GM+ or negative (-) are indicated (a, b). Numbers above male diabetic 
rnernbers (•) or female diabetic members (e) are number in generation and those below are ages at diagnosis. I, impaired glucose 
tolerance; 0 normal glucose tolerance; o reported normal and untested; + groups of siblings untested and of unspecified sex . 
With number of individuals given; Ml, myocardial infarction; PVD, peripheral vascular disease; A, amputation; G, gangrene; N, 
neuropathy; Ang, angina pectoris; R, retinopathy; R-8, retinopathy and blindness; NP, nephropathy. All diabetic members of 
generations I and II, along with 111-29 and 111-30, are deceased. (From Fajan et aJ.2 with kind permission of Elsevier Science Ltd, 
Kidlington, Oxford, UK.) 
have been treated successfully with sulphonylurea drugs, 
Up to the present, and 1 is using diet alone, although 
sufphonylurea therapy is indicated because he has 
recently developed fasting hyperglycaemia. Sub-
sequently, by routine blood glucose testing diabetes was 
diagnosed in 10 of the 20 members of generation IV 
Who are offspring of diabetic subjects of generation Ill, 
and up to the present time in 4 members of generation 
V. None of them are obese. Ages of diagnosis were 9-
14 years in 12 of these patients with diabetes. Patient 
IV-144 has typical IDDM. Among offspring of 11-2, 3 of 
the 5 diabetic members (111-3, 111-4, 111-8) have MODY 
segregating in generations 111-V (Figure 1 (b)). 1-1 (Figure 
1 (a)) had 3 offspring, 2 of whom had diagnosed diabetes 
(R branch, Generation II, not shown in Figure 1 ). Among 
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their 10 offspring in generation Ill, 6 have or have had 
diagnosed NIDDM. Of 12 tested subjects in Generation 
IV who are offspring of a diabetic parent, 5 have diabetes. 
Thus, diabetes is inherited in the autosomal pattern of 
MODY in the R branch as well. None of them are obese. 
MODY is usually asymptomatic in younger age groups, 
although some patients may have symptoms, particularly 
if stressed by an infection. Unless searched out by 
prospective testing, because of a family history of NIDDM 
in two or more generations, in a young person or during 
a pregnancy, a clinical diagnosis of diabetes is frequently 
not made in many members of such families until middle 
or late adult life. Thus, age of diagnosis cannot be 
equated to age of onset of hyperglycaemia. Younger 
family members must be screened before typical MODY 
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can be excluded. As demonstrated in the RW pedigree 
in which MODY is linked to chromosome 20q (see 
below), it can be demonstrated by repeated testing in 
younger members that there may be a variable rate of 
progression from nondiagnostic (but not normal) glucose 
tolerance tests to IGT, from IGT to diabetic glucose 
tolerance with normal fasting plasma glucose levels (up 
to 18 years), and very slow or rapid progression to 
fasting hyperglycaemia (0.5 to 27 years). In contrast, 
other individuals with MODY from this pedigree may 
have fasting hyperglycaemia or rapid progression from 
an early age, even though they are asymptomatic. Among 
nonobese diabetic subjects of the RW pedigree in 
generations 111-V approximately 80% have had fasting 
hyperglycaemia at diagnosis or on follow-up. Plasma 
glucose levels at first detection of fasting hyperglycaemia 
range between 140 and 366 mg dl-1• Approximately 
30% had fasting hyperglycaemia diagnosed between the 
ages of 9 and 14 years or within a 1 to 3 year follow-
up. Among the known diabetic patients from generations 
111-V of the RW pedigree approximately 30% have 
become insulin-requiring. Typical microangiopathic and 
macroangiopathic complications may occur similar to 
those seen in other patients with NIDDM.3•4 
In contrast to MODY linked to chromosome 20q, as 
present in the RW pedigree, MODY due to mutations in 
the glucokinase gene on chromosome 7p (see below) is 
a relatively mild form of diabetes with mild fasting 
hyperglycaemia and IGT in the majority that may be 
recognized by biochemical testing at an even younger 
age (mean 7 ± 4 years, minimal age, 1 year).5 There 
appears to be little progression of hyperglycaemia on 
follow-up.6 •7 Severe fasting hyperglycaemia and vascular 
complications appear to be infrequent (Table 1 ). Thus 
MODY due to glucokinase mutations appears to be a 
much milder and relatively benign form of hypergly-
caemia, in contrast to the more severe diabetes seen in 
MODY linked to chromosome 20q that more closely 
resembles classical NIDDM. 
Molecular Genetics of MODY 
MODY fulfils some of the fundamental requirements for 
defining the molecular genetic basis of any disorder by 
linkage analysis because of its established autosomal 
dominant inheritance and the availability of large multig-
enerational kindreds. The RW pedigree was first used 
for a search of diabetes susceptibility genes by this 
technique. The initial linkage strategy was to search for 
'candidate genes', that is genes involved in carbohydrate 
and lipid metabolism. Such genes were excluded as the 
cause of NIDDM in the RW pedigree.8 In a subsequent 
systematic gene mapping approach (positional cloning), 
DNA polymorphisms in the adenosine deaminase gene 
(ADA) and the anonymous locus D20S16 on the long 
arm of chromosome 20 were found to cosegregate with 
MODY8- 13 in members with diabetes of both W and R 
branches. There are no recombinations between these 
markers and MODY and the lod score presently exceeds 
17.0 at a recombination fraction of 0.00, indicating that 
the gene responsible for MODY in this family is tightly 
linked to these genes. 
The identification of genetic markers for MODY in the 
RW pedigree has shown that linkage studies of large 
MODY families can uncover DNA markers for 
NIDDM.8 •10 The gene responsible for MODY in the RW 
pedigree is unknown but is in the region of ADA and 
D20S16 on chromosome 20q. DNA typing can identify 
'at risk' subjects, i.e. genetic screening for prediabetes 
is possible in the RW pedigree. Identification of the 
Table 1. Differences between MODY due to mutations in the glucokinase gene (chromosome 7p) and the diabetes-susceptibility 
gene on chromosome 20q 
Fasting hyperglycaemia (>140 mg dl-1) 
Postprandial hyperglycaemia 
Progression of hyperglycaemia 
Minimum age at diagnosis 
Need for insulin therapy 
Vascular complications 
AIRglu• 
ISRb during graded IV glucose infusion: 
mildly diabetic MOOY 
nondiabetic subjects with genetic markers 
Glucose priming of ISR 
MODY 
nondiabetic subjects with genetic markers 
Postulated abnormality in ~-cell function 
"AIRglu, acute insulin response to glucose. 
bJSR, insulin secretion rate. 
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Glucokinase gene 
0-++ 
0- ++ 
0 
1 year 
Uncommon (2%) 
Rare 
Normal-! 
!-!! 
Not available 
Normal (45% increase) 
Not available 
Glucose sensing 
Chromosome 20q 
0 - + + + + (approx. 80%) 
++- ++++ 
++-++++ 
7-9 years 
Common (approx. 30%) 
++ 
!!-absent 
!!! 
Ul 
Absent 
Absent 
Locus beyond glucose sensing or 
decrease in /3-cell mass 
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MODY gene on chromosome 20 may disclose previously 
unrecognized mechanisms controlling insulin secretion 
and lead us closer to an understanding of the pathogenesis 
of MODY in this pedigree, with possible application to 
NIDDM in general. Such studies may lead eventually to 
the prevention, improved treatment, or even a cure for 
this and other forms of NIDDM. 
Because there is heterogeneity between MODY families 
by hormonal and metabolic characterization, 14 it was 
postulated that additional NIDDM susceptibility genes 
or modifying determinants would be found.8 Indeed, this 
occurred shortly thereafter. Tight linkage between MODY 
and the glucokinase gene on chromosome 7p was found 
in approximately 60% of 32 French MODY families,5·15 
in one British family6·16 and two in Japanese families. 17·18 
Glucokinase is the first rate-limiting enzyme in the 
metabolism of glucose by the pancreatic f3-cell. It causes 
the phosphorylation of glucose to glucose-6-phosphate 
initiating glycolysis which is essential for insulin secretion. 
This enzyme has been postulated to be the glucose 
sensing mechanism for insulin secretion.19 Subsequently, 
a host of different mutations (nonsense, missense or 
deletions) in the glucokinase gene have been found in 
members of MODY families in which MODY is linked 
to the glucokinase gene.5·1&-18·20-23 They are believed to 
cause diabetes by a gene dosage mechanism with a 
modest decrease in glucokinase activity increasing the 
glucose threshold for insulin secretion. Matschinsky has 
suggested that a 15% decrease in glucokinase activity 
may raise the threshold of insulin secretion from 5 to 6 
mmol.19 Mutations in the glucokinase gene are the most 
common genetic cause of NIDDM identified to date, 
particularly among MODY pedigrees. The RW pedigree 
is the only large pedigree in which tight linkage of 
MODY to chromosome 20q has been established. 
Evidence consistent with linkage to chromosome 20q 
has been found in two French5·15 and one Canadian 
(D.W.Bowden, E, Colle, unpublished results) MODY pedi-
grees. 
In addition to the glucokinase gene and the gene on 
chromosome 20, there must be other loci that can cause 
MODY as MODY pedigrees have been described that 
show no evidence of linkage with glucokinase or markers 
on chromosome 20.5,&,11,15,24 
/3-Ce/1 Function and Insulin Resistance 
In the RW pedigree, the majority of MODY subjects 
Who were offspring of 11-2 and 11-5 have a delayed 
and subnormal insulin secretory response to orally 
administered glucose, strongly suggesting an impairment 
of /3-cell function. In these individuals impaired /3-cell 
function, although moderate in magnitude, appears to 
be the major underlying pathogenetic factor for abnormal 
glucose levels. The low insulin secretory response to 
glucose may occur from childhood onwards and before 
glucose intolerance appears. This is demonstrated by 
insulin levels during the oral glucose tolerance test in 
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nondiabetic subjects who are genetic marker negative 
or positive (Figure 2). The nondiabetic marker-negative 
subjects had a mean insulin response to the administration 
of glucose which was almost identical to that previously 
reported in 150 control subjects without a family history 
of diabetes.14 In contrast, nondiabetic subjects who are 
marker-positive had a decreased insulin response to 
glucose, maximal levels at 1 h being approximately one-
half of that of the marker-negative subjects. Subjects 
with IGT had a similar or slightly lower insulin response 
to glucose. Other groups of subjects with IGT have been 
reported to have normal or elevated levels of plasma 
insulin during the OGTI as compared to control sub-
jects.25·26 MODY subjects with fasting plasma glucose 
levels below 140 mg dl-1 showed a further decline in 
the insulin response with additional progressive decreases 
in diabetic subjects with fasting plasma glucose concen-
trations between 140 and 200 and greater than 200 
mg dl-1 (Figure 2). The defective insulin secretory 
response was postulated to be a manifestation of the 
basic genetic defect that leads to diabetes only when 
additional superimposed environmental factors super-
vene.M Pathological insulin resistance does not appear 
to be an important contributing factor because of normal 
sensitivity to intravenously administered insulin and 
because of the usually low insulin requirement in insulin-
treated diabetic members of the RW pedigree. 
In diabetic MODY patients linked to a mutation in 
the glucokinase gene, there is evidence of decreased 
insulin secretion by continuous glucose infusion6·7·27 
although the acute insulin response to glucose was 
within normal limits.7·27 A decreased insulin secretory 
response to orally administered glucose has also been 
reported in glucokinase-linked MODY.18 In addition, no 
evidence of insulin resistance has been reported 7•27 in 
such patients. This is in contradistinction to patients with 
other types of NIDDM, most of whom are obese, in 
whom it has been found or postulated that insulin 
resistance is a more important factor than insulin· 
deficiency in the pathogenesis of diabetes.28•29 
Since chronic hyperglycaemia has been reported to 
be associated with both a decrease of insulin sensitivity 
as well as an impairment of /3-cell function, the question 
of which is the primary genetic defect in MODY or 
NIDDM is very difficult to address in diabetic patients.28 
Since we now have genetic markers for MODY in 
the RW pedigree, we undertook to determine early 
abnormalities of insulin action and of insulin secretion 
in nondiabetic subjects of the pedigree with and without 
the gene markers to ascertain which of these defects 
might be primary. Six nondiabetic marker-negative and 
5 nondiabetic marker-positive members of the RW 
pedigree were studied, as were 4 mildly diabetic marker-
positive family members. Unrelated, young, healthy 
subjects served as comparison groups.30 Insulin action 
and insulin secretion were assessed with a frequently 
sampled intravenous glucose tolerance test (Bergman 
Minimal Model). Insulin secretion was further assessed 
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Figure 2. Plasma concentrations of glucose and insulin during oral glucose tolerance tests (1.75 g kg-1 body weight) in groups of 
subjects of the RW pedigree 
during constant low dose glucose infusion by deconvol-
ution of plasma C-peptide and by pulse analysis. 
The non-diabetic marker-positive group had normal 
sensitivity to insulin and unimpaired acute insulin 
response to intravenous glucose. However, the nondia-
betic marker-positive group had decreased mean plasma 
C-peptide concentration, reduced absolute amplitude of 
insulin secretory ultradian oscillations, and decreased 
insulin secretion rate during prolonged glucose 
infusion.2•30 These responses to prolonged glucose 
infusion were similar to those observed in the diabetic 
group, who, in addition, also had a decreased or absent 
acute insulin response to intravenous glucose.30 No 
alterations of insulin secretion were observed in the 
nondiabetic marker-negative family members or in the 
comparison groups. Deranged and deficient insulin 
secretion, and not insulin resistance, appears to be 
the genetic or primary abnormality that characterizes 
nondiabetic individuals who are predisposed to MODY 
in the RW pedigree. Prolonged glucose infusion studies 
may reveal qualitative and quantitative defects in insulin 
secretion not identified by the acute insulin response to 
intravenous glucose. Furthermore, use of the acute insulin 
response to glucose may not be able to exclude a 
primary J3-cell defect in the pathogenesis of any form 
of NIDDM.30 
Quantitative and qualitative differences in insulin 
secretory defects between MODY with glucokinase 
mutations and MODY with mutation on chromosome 
20q have been found by studies with acute and more 
prolonged intravenous infusions of glucose. MODY 
subjects with glucokinase mutations have a first phase 
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insulin response to glucose which is in the normal range 
or only slightly decreased7•27 while mildly diabetic 
patients with a chromosome 20 mutation have a 
decreased or absent acute response to glucose.30 During 
stepped glucose infusions, both groups of MODY subjects 
(including nondiabetic marker-positive subjects of the 
RW pedigree) showed a decreased response of the 13-
cell to glucose resulting in a downward shift in the 
glucose/insulin secretion rate dose-response curve to the 
right which was more severe in RW subjects with a 
failure of J3-cell sensitivity to improve after prolonged 
priming with intravenous glucose.27•31 
Although the specific genetic defect causing MODY 
in the RW pedigree is unknown, the quantitative and 
qualitative differences in insulin secreting defects in these 
subjects suggests a different mechanism of the J3-cell 
dysfunction which may distinguish this form of MODY 
from that due to mutations in the glucokinase gene 
(Table 1 ). The greater severity of the insulin secretory 
defect in mildly diabetic and nondiabetic subjects 
with mutation in the diabetes susceptibility gene on 
chromosome 20q correlates with a greater severity of 
hyperglycaemia, a greater need for insulin therapy and 
a greater prevalence of vascular complications seen in 
these diabetic subjects than in those with mutations in 
the glucokinase gene (Table 1 ). 
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